Latest Conference Articles

February 27th 2015, 2:50pm

Genitourinary Cancers Symposium (ASCO GU)

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses a study looking at androgen receptor splice variant 7 (AR-V7) in metastatic castration-resistant prostate cancer (mCRPC).

February 27th 2015, 1:20pm

PER® Miami Breast Cancer Conference

Tumor genome profiling identifies driver mutations in breast tumors, however, it is still too early to use this information in clinical decision making.

February 27th 2015, 1:02pm

Genitourinary Cancers Symposium (ASCO GU)

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado, discusses the performance of the cell cycle progression (CCP) assay for prostate cancer.

February 27th 2015, 12:03pm

PER® Miami Breast Cancer Conference

While not appropriate for all patients with ER-positive breast cancer, neoadjuvant endocrine therapy could play an important role in select groups of women with comorbidities or those with ER-rich/luminal A disease.

February 27th 2015, 11:56am

Genitourinary Cancers Symposium (ASCO GU)

Andrew Loblaw, MD, FRCPC, MSc, clinician scientist, radiation oncologist, Sunnybrook Health Sciences Centre, discusses a study that looked at using active surveillance to monitor men with intermediate-risk prostate cancer.

February 27th 2015, 11:08am

Genitourinary Cancers Symposium (ASCO GU)

The beneficial effect of abiraterone acetate on overall survival in men with progressive metastatic CRPC in the COU-AA-302 study becomes even more pronounced after adjustment for crossover from placebo to active treatment.

February 27th 2015, 10:11am

PER® Miami Breast Cancer Conference

The FDA's recent approval of the first PARP inhibitor suggests that this new class of targeted therapy has great potential to help not only patients with ovarian cancer for whom the agent is indicated but also individuals with breast cancer.

February 27th 2015, 9:44am

Genitourinary Cancers Symposium (ASCO GU)

Androgen deprivation therapy with or without chemotherapy led to similar survival in men with advanced, metastatic hormone-sensitive prostate cancer, an updated analysis of a randomized trial showed.

February 27th 2015, 7:57am

Genitourinary Cancers Symposium (ASCO GU)

A phase I study conducted at the NIH, combining a fixed dose of PROSTVAC with escalating doses of the checkpoint inhibitor ipilimumab, produced encouraging survival results in mCRPC.

February 26th 2015, 1:46pm

PER® Miami Breast Cancer Conference

Debu Tripathy, MD, professor of medicine, chair, department of breast medical oncology, The University of Texas MD Anderson Cancer Center, discusses the possibility of one day being able to cure metastatic breast cancer.

February 26th 2015, 1:10pm

PER® Miami Breast Cancer Conference

Deanna J. Attai, MD, breast surgeon, assistant clinical professor of surgery, David Geffen School of Medicine, University of California, Los Angeles, explains how social media can help physicians.

February 26th 2015, 11:51am

Genitourinary Cancers Symposium (ASCO GU)

Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses a study that looked at the impact of body mass index (BMI) on outcomes of patients with metastatic renal cell carcinoma (mRCC).

February 26th 2015, 11:50am

PER® Miami Breast Cancer Conference

The landscape of breast cancer care is shifting rapidly, but that doesn't worry the organizers of the 32nd Annual Miami Breast Cancer Conference.

February 26th 2015, 10:32am

PER® Miami Breast Cancer Conference

With the evolution of treatment under way, OncLive interviewed three world-renowned experts in the field: Joanne L. Blum, MD, PhD, Adam M. Brufsky, MD, PhD, and Harold J. Burstein, MD, PhD.

February 26th 2015, 8:47am

Genitourinary Cancers Symposium (ASCO GU)

Rana R. McKay, MD, discusses a study looking at statins and survival outcomes in patients with metastatic renal cell carcinoma.

February 23rd 2015, 3:29pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Eduardo Sotomayor, MD, the Susan and John Sykes Endowed Chair in Hematologic Malignancies at Moffitt Cancer Center, discusses the future of personalized medicine in lymphoma.

February 23rd 2015, 3:10pm

Genitourinary Cancers Symposium (ASCO GU)

The proportion of men diagnosed with intermediate- or high-risk cancer, based on blood PSA level, increased by nearly 6% from 2011 to 2013.

February 23rd 2015, 3:10pm

Genitourinary Cancers Symposium (ASCO GU)

The risk of dying from prostate cancer increased fourfold when active surveillance was used to monitor men with intermediate-risk disease compared with low-risk prostate cancer patients.

February 23rd 2015, 3:10pm

Genitourinary Cancers Symposium (ASCO GU)

Neither sorafenib nor sunitinib improved outcomes when administered after surgery to patients with locally advanced renal cell carcinoma (RCC), according to results from the phase III ASSURE trial, which were presented at a presscast held ahead of the 2015 Genitourinary Cancers Symposium.

February 23rd 2015, 3:10pm

Genitourinary Cancers Symposium (ASCO GU)

A new study has shown that men with a history of testicular cancer have a higher incidence of developing prostate cancer, including intermediate or high-risk prostate cancer, compared to those without a history of testicular cancer.